KR20050094461A - A therapeutic composition for the treatment of hiv-1 and hiv-2 - Google Patents

Abstract

A pharmaceutical mixture and a method of its production of a therapeutic composition for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment.

Description

Therapeutic composition for the treatment of HIV-1 and HIV-1-2 A THERAPEUTIC COMPOSITION FOR THE TREATMENT OF HIV-1 AND HIV-2}

The present invention provides a pharmaceutical mixture for preventing HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS and HIV-1 and HIV-2. A method for preparing a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of viral infection and in AIDS.

As used herein, the terms “treatment of HIV” and “treatment of HIV in patients in need of such treatment” refer to the treatment of HIV-1 and / or HIV-2 patients. The term "blocking HIV replication" also means blocking HIV-1 and / or HIV-2 virus replication. The term “HIV virus” also refers to HIV-1 and / or HIV-2 virus. The term “HIV infection” means HIV-1 and / or HIV-2 infection.

The present invention provides a pharmaceutical mixture for preventing HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS and HIV-1 and HIV-2. A method for preparing a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of viral infection and in AIDS.

The mixture is used for the treatment of AIDS, ie AIDS.

Summary of the Invention

The present invention relates to pharmaceutical mixtures for the prevention of HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system in HIV-1 and HIV-2 virus infections and AIDS. And / or auxiliary substances, wherein at least 10 of them are present as active substances; Allocryptopin is present in an amount from 1.0 mg to 10.0 mg; Nimodipine is present in an amount of 20.0 mg to 100.0 mg; Potassium iodide is present in an amount of 120.0 mg to 560.0 mg; Potassium iodide is present in an amount of 30.0 mg to 140.0 mg; Inulin is present in an amount of 125.0 mg to 375.0 mg; Silver is present in an amount of 0.10 mg to 0.50 mg; Zinc is present in an amount of 10.0 mg to 20.0 mg; Chromium is present in an amount from 0.05 mg to 0.20 mg; Orotic acid is present in an amount from 150.0 mg to 500.0 mg; Desferin is present in an amount of 100.0 mg to 300.0 mg.

summary

The present invention relates to a method for preparing pharmaceutical mixtures and therapeutic compositions for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS. The therapeutic composition consists of a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin. In one embodiment of the invention, the pharmaceutical mixtures and methods also include pharmaceutically effective amounts of tarasosterol and B-sitosterol.

Detailed description of the invention

The present invention also relates to a method for preparing a pharmaceutical mixture for preventing replication of HIV-1 and HIV-2 viruses in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS. Allocriptopin in an amount of from 1 to 10.0 mg; Nimodipine in an amount of 20.0 mg to 100.0 mg; Potassium iodide in an amount of 120.0 mg to 560.0 mg; Potassium iodide in an amount of from 30.0 mg to 140.0 mg; Inulin in an amount of 125.0 mg to 375.0 mg; Silver in an amount of 0.10 mg to 0.50 mg; Zinc in an amount of 10.0 mg to 20.0 mg; Chromium in an amount of 0.05 mg to 0.20 mg; Orotic acid in an amount of 150.0 mg to 500.0 mg; Desperin in an amount of 100.0 mg to 300.0 mg is mixed at room temperature until an approximately homogeneous mixture is formed and then compressed to form a tablet or coated tablet or wafer, suppository, effervescent powder, gel or colloidal solution or suspension, syrup And soluble salts in body fluids or liquids or ampoules for intramuscular or intravenous injection.

In existing applications relating to the treatment of HIV infection or AIDS patients, no medicament / pharmaceutical preparations have been disclosed to prevent HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system. .

The present invention is intended to explain that HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system is an exeitono-excimer interaction between HIV-1 and HIV-2 viruses and CD4 cells of the human immune system. do.

Initiation of treatment aimed at the treatment of HIV-1 and HIV-2 viral infections and AIDS results in a decrease in the transporter that completely blocks the mechanisms of action that cause HIV-1 and HIV-2 replication in the patient's body.

The following substances have been demonstrated to help: Alkaloids, Nimodipine, Potassium Iodide, Potassium Iodide, Inulin, Silver, Zinc, Chromium, Orlot Found in AlloCryptopin, Chelidonium maius Plants Acid and desferrin. Tarasosterol and B-sitosterol are also included in this.

Allocrippine is a nucleotide phosphodiesterase blocker, nimodipine is a calcium channel blocker, potassium iodide produces iodine free radicals when mixed with potassium iodide in an acidic environment, inulin is a polysaccharide that does not degrade in the body, It is known that, zinc and chromium are elements that play a role in enzyme action, desferin makes iron ions into chelate compounds, and orotic acid is a precursor to nucleotide compounds.

However, the materials mentioned above have never been used together and in particular they have not been used together in therapeutic applications as disclosed herein.

It is an object of the present invention to provide a pharmaceutical mixture which prevents the replication of HIV-1 and HIV-2 viruses in CD4 + cells of the human immune system.

The present invention provides pharmaceutical mixtures for the prevention of HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS, It includes known carriers and / or auxiliary substances, characterized in that at least ten chemical substances are present as active substances:

Allocyprupine is present in an amount from 1.0 mg to 10.0 mg,

Nimodipine is present in an amount from 20.0 mg to 100.0 mg,

Potassium iodide is present in an amount from 120.0 mg to 560.0 mg,

Potassium iodide is present in an amount from 30.0 mg to 140.0 mg,

Inulin is present in an amount from 125.0 mg to 375.0 mg,

Silver is present in an amount from 0.10 mg to 0.50 mg,

Zinc is present in an amount from 10.0 mg to 20.0 mg,

Chromium is present in an amount from 0.05 mg to 0.20 mg,

Orotic acid is present in an amount from 150.0 mg to 500.0 mg,

Desferin is present in an amount from 100.0 mg to 300.0 mg.

-Allokryptopin content is 10.0mg,

Nimodipine content is 100.0mg,

-Potassium iodide content is 560.0 mg,

-Potassium iodide content is 140.0 mg,

-Inulin content is 375.0 mg,

-Has a silver content of 0.50 mg,

-Zinc content is 20.0 mg,

Chromium content is 0.20 mg,

-Orotic acid content is 500.0 mg,

Useful when desperin content is 300.0mg.

-Allocryptofine content is 4.50mg,

Nimodipine content is 60.0mg,

-Potassium iodide content is 340.0 mg,

-Potassium iodide content is 85.0 mg,

-Inulin content is 250.0 mg,

-Has a silver content of 0.30 mg,

-Zinc content is 15.0 mg,

Chromium content is 0.125 mg,

-Ortho acid content is 325.0 mg,

It is beneficial when the desferin content is 200.0mg.

-Allocryptofine content is 4.50mg,

Nimodipine content is 60.0mg,

-Potassium iodide content is 340.0 mg,

-Potassium iodide content is 85.0 mg,

-Inulin content is 250.0 mg,

-Has a silver content of 0.30 mg,

-Zinc content is 15.0 mg,

Chromium content is 0.125 mg,

-Ortho acid content is 325.0 mg,

Desperin content is 200.0 mg,

-Tarasosterol content is 350mg,

It is beneficial when the B-sitosterol content is 400 mg.

-Allokryptopin content is 1.0mg,

-Nimodipine content is 20.0 mg,

-Potassium iodide content is 120.0 mg,

-Potassium iodide content is 30.0 mg,

-Inulin content is 125.0 mg,

-Has a silver content of 0.10 mg,

Zinc content is 10.0 mg,

Chromium content is 0.05 mg,

-Ortho acid content is 250.0 mg,

-The desperin content is 100.0 mg,

-The tarasasterol content is 250mg,

It is beneficial when the B-sitosterol content is 300 mg.

-Allokryptopin content is 1.0mg,

-Nimodipine content is 20.0 mg,

-Potassium iodide content is 120.0 mg,

-Potassium iodide content is 30.0 mg,

-Inulin content is 125.0 mg,

-Has a silver content of 0.10 mg,

Zinc content is 10.0 mg,

Chromium content is 0.05 mg,

-Ortho acid content is 250.0 mg,

It is beneficial when the desperin content is 100.0 mg.

The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin versus silver to zinc to chromium to orotic acid to desferin is generally 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250 Useful when maintained at: 100.

It is advantageous when the mixture of these ingredients is in the form of tablets or coated tablets or wafers or suppositories or effervescent powders or gels or colloidal solutions.

It is advantageous when the mixture of these ingredients is in the form of a suspension or syrup or a salt soluble in bodily fluids or a liquid for intramuscular or intravenous injection.

Preparation of pharmaceutical mixtures to prevent HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS results in a homogeneous mixture of the following components: Mix at room temperature until:

Allocriptopin in an amount from 1.0 mg to 10.0 mg,

Nimodipine in an amount of 20.0 mg to 100.0 mg,

Potassium iodide in an amount of 120.0 mg to 560.0 mg,

Potassium iodide in an amount of from 30.0 mg to 140.0 mg,

Inulin in an amount of 125.0 mg to 375.0 mg,

Silver in an amount of 0.10 mg to 0.50 mg,

Zinc in an amount of 10.0 mg to 20.0 mg,

Chromium in an amount of from 0.05 mg to 0.20 mg,

Orotic acid in an amount from 150.0 mg to 500.0 mg,

Desferin in an amount of 100.0 mg to 300.0 mg.

-Allokryptopin content is 10.0mg,

Nimodipine content is 100.0mg,

-Potassium iodide content is 560.0 mg,

-Potassium iodide content is 140.0 mg,

-Inulin content is 375.0 mg,

-Has a silver content of 0.50 mg,

-Zinc content is 20.0 mg,

Chromium content is 0.20 mg,

-Orotic acid content is 500.0 mg,

Useful when desperin content is 300.0mg.

-Allocryptofine content is 4.50mg,

Nimodipine content is 60.0mg,

-Potassium iodide content is 340.0 mg,

-Potassium iodide content is 85.0 mg,

-Inulin content is 250.0 mg,

-Has a silver content of 0.30 mg,

-Zinc content is 15.0 mg,

Chromium content is 0.125 mg,

-Ortho acid content is 325.0 mg,

It is beneficial when the desferin content is 200.0mg.

-Allokryptopin content is 1.0mg,

-Nimodipine content is 20.0 mg,

-Potassium iodide content is 120.0 mg,

-Potassium iodide content is 30.0 mg,

-Inulin content is 125.0 mg,

-Has a silver content of 0.10 mg,

Zinc content is 10.0 mg,

Chromium content is 0.05 mg,

-Ortho acid content is 250.0 mg,

It is beneficial when the desperin content is 100.0 mg.

The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin versus silver to zinc to chromium to orotic acid to desferin is generally 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250 Useful when maintained at: 100.

Pharmaceutical mixtures and methods for preparing the same also include pharmaceutically effective amounts of tarasosterol and B-sitosterol. The pharmaceutical mixture and the method for preparing the same are allocryptopine in an amount of 1.0 mg to 10.0 mg, nimodipine in an amount of 20.0 mg to 100.0 mg, potassium iodide in an amount of 120.0 mg to 560.0 mg, and iodine in an amount of 30.0 mg to 140.0 mg Potassium acid, inulin in an amount of 125.0 mg to 375.0 mg, silver in an amount of 0.10 mg to 0.50 mg, zinc in an amount of 10.0 mg to 20.0 mg, chromium in an amount of 0.05 mg to 0.20 mg, orotic acid in an amount of 150.0 mg to 500.0 mg, Desferin in an amount of 100.0 mg to 300.0 mg, taraxasterol in an amount of 250 mg to 400 mg and B-sitosterol in an amount of 300 mg to 500 mg are mixed at room temperature until a homogeneous mixture is formed, and then compressed or purified tablets It is advantageous when produced in the form or as a wafer, suppository, effervescent powder, gel or colloidal solution or suspension, syrup, salt soluble in bodily fluids or liquid or ampoule for intramuscular or intravenous injection.

The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to potassium inulin to silver to zinc to chromium to orotic acid to desferrin to tarasasterol to B-sitosterol is generally 1: 20: 120: 30: 125 Useful when maintained at: 0.1: 10: 0.05: 250: 100: 400: 500.

The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to potassium inulin to silver to zinc to chromium to orotic acid to desferrin to tarasasterol to B-sitosterol is generally 1: 20: 120: 30: 125 It is also beneficial when maintained at: 0.1: 10: 0.05: 250: 100: 350: 400.

It is advantageous when the mixture of these ingredients is in the form of tablets or coated tablets or wafers or suppositories or effervescent powders or gels or colloidal solutions.

It is advantageous when the mixture of these ingredients is in the form of a suspension or syrup or a salt soluble in bodily fluids or a liquid for intramuscular or intravenous injection.

The beneficial effects of the pharmaceutical mixtures of the present invention not only prevent the intracellular actions associated with HIV-1 and HIV-2 virus replication but also the mechanism of action of attaching the gp 160 protein of the HIV virus capsule to the receptors of CD4 + cells of the human immune system. will be.

Example  One

Content of Pharmaceutical Mixtures:

-The amount of allocrippinin is 10.0 mg,

Nimodipine amount is 100.0mg,

The amount of potassium iodide is 560.0 mg,

The amount of potassium iodide is 140.0 mg,

The amount of inulin is 375.0 mg,

-The amount of silver is 0.50 mg,

-The amount of zinc is 20.0 mg,

-The amount of chromium is 0.20 mg,

-The amount of oroic acid is 500.0 mg,

Desperin amount is 300.0 mg

Preparation of Pharmaceutical Mixtures:

AlloCryptopin 10.0mg, Nimodipine 100.0mg, Potassium Iodide 560.0mg, Potassium Iodide 140.0mg, Inulin 375.0mg, Silver 0.50mg, Zinc 20.0mg, Chromium 0.20mg, Orotic Acid 500.0mg, Desperin 300.0mg Mixed in.

After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed. The mixture was then compressed to prepare tablets, coated tablets or wafers, suppositories, effervescent powders, gels or colloidal solutions.

Example  2

Content of Pharmaceutical Mixtures:

-The amount of allocrippinin is 1.0mg,

Nimodipine amount is 20.0mg,

The amount of potassium iodide is 120.0 mg,

-The amount of potassium iodide is 30.0 mg,

The amount of inulin is 125.0 mg,

-The amount of silver is 0.10 mg,

-The amount of zinc is 10.0 mg,

The amount of chromium is 0.05 mg,

The amount of oroic acid is 150.0 mg,

Desperin amount is 100.0 mg.

Preparation of Pharmaceutical Mixtures:

AlloCryptopin 1.0mg, Nimodipine 20.0mg, Potassium Iodide 120.0mg, Potassium Iodide 30.0mg, Inulin 125.0mg, Silver 0.10mg, Zinc 10.0mg, Chromium 0.05mg, Orotic Acid 150.0mg, Desperin 100.0mg Mixed in.

After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed.

The mixture was then prepared as suspensions, syrups, salts soluble in body fluids or liquids or ampoules for intramuscular or intravenous injection.

Example  3

Content of Pharmaceutical Mixtures:

-The amount of allocrippinin is 10.0 mg,

Nimodipine amount is 100.0mg,

The amount of potassium iodide is 560.0 mg,

The amount of potassium iodide is 140.0 mg,

The amount of inulin is 375.0 mg,

-The amount of silver is 0.50 mg,

-The amount of zinc is 20.0 mg,

-The amount of chromium is 0.20 mg,

-The amount of oroic acid is 500.0 mg,

-The amount of desperin is 300.0 mg,

-The amount of tarasasterol is 400mg,

The amount of B-sitosterol is 500 mg.

Preparation of Pharmaceutical Mixtures:

AlloCryptopin 10.0mg, Nimodipine 100.0mg, Potassium Iodide 560.0mg, Potassium Iodide 140.0mg, Inulin 375.0mg, Silver 0.50mg, Zinc 20.0mg, Chromium 0.20mg, Orotic Acid 500.0mg, Desperin 300.0mg, Tara 400 mg of sasterol and 500 mg of B-sitosterol were mixed at room temperature.

After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed. The mixture was then compressed to prepare tablets, coated tablets or wafers, suppositories, effervescent powders, gels or colloidal solutions.

Example  4

Content of Pharmaceutical Mixtures:

-The amount of allocrippinin is 1.0mg,

Nimodipine amount is 20.0mg,

The amount of potassium iodide is 120.0 mg,

-The amount of potassium iodide is 30.0 mg,

The amount of inulin is 125.0 mg,

-The amount of silver is 0.10 mg,

-The amount of zinc is 10.0 mg,

The amount of chromium is 0.05 mg,

The amount of oroic acid is 150.0 mg,

-The amount of desperin is 100.0 mg,

-The amount of tarasasterol is 250mg,

The amount of B-sitosterol is 300 mg.

Preparation of Pharmaceutical Mixtures:

AlloCryptopin 1.0mg, Nimodipine 20.0mg, Potassium Iodide 120.0mg, Potassium Iodide 30.0mg, Inulin 125.0mg, Silver 0.10mg, Zinc 10.0mg, Chromium 0.05mg, Orotic Acid 150.0mg, Desperin 100.0mg, Tara 250 mg of sasterol and 300 mg of B-sitosterol were mixed at room temperature.

After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed.

The mixture was then prepared as suspensions, syrups, salts soluble in body fluids or liquids or ampoules for intramuscular or intravenous injection.

The term "pharmaceutically effective amount" refers to a pharmaceutical mixture of the present invention (including a mixture of allocryptopine, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin). It should be understood that it refers to an effective amount. Substantial dosages, components, and methods of administration of the pharmaceutical compositions of the present invention may vary to achieve the desired therapeutic response in a particular patient. The dosage chosen will depend on the activity of the particular compound, the route of administration, the severity and condition of the condition to be treated and the previous history of the patient to be treated. However, it is within the skill in the art to begin administering the compound at an amount lower than necessary to achieve the desired therapeutic effect and to increase the dosage until the desired effect is achieved.

Claims (31)

In a therapeutic composition for the treatment of HIV, the therapeutic composition is a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin. A therapeutic composition consisting of. The method of claim 1, wherein the allocliptopin is present in an amount of about 1.0 mg to about 10.0 mg, nimodipine is present in an amount of about 20.0 mg to about 100.0 mg, and potassium iodide is about 120.0 mg to about 560.0 mg Potassium iodide in an amount of about 30.0 mg to about 140.0 mg, inulin is present in an amount of about 125.0 mg to about 375.0 mg, and silver is present in an amount of about 0.10 mg to about 0.50 mg Zinc is present in an amount of about 10.0 mg to about 20.0 mg, chromium is present in an amount of about 0.05 mg to about 0.20 mg, orotic acid is present in an amount of about 150.0 mg to about 500.0 mg and desferin A therapeutic composition present in an amount of about 100.0 mg to about 300.0 mg. The method of claim 1, wherein the allocliptopin is present in an amount of about 10.0 mg, nimodipine is present in an amount of about 100.0 mg, potassium iodide is present in an amount of about 560.0 mg, and potassium iodide is about 140.0 in an amount of mg, inulin is present in an amount of about 375.0 mg, silver is present in an amount of about 0.50 mg, zinc is present in an amount of about 20.0 mg, chromium is present in an amount of about 0.20 mg, The therapeutic composition wherein orotic acid is present in an amount of about 500.0 mg and desferin is present in an amount of about 300.0 mg. The method of claim 1, wherein the allocliptopin is present in an amount of about 4.5 mg, nimodipine is present in an amount of about 60.0 mg, potassium iodide is present in an amount of about 340.0 mg, and potassium iodide is about 85.0 in an amount of mg, inulin is present in an amount of about 250.0 mg, silver is present in an amount of about 0.30 mg, zinc is present in an amount of about 15.0 mg, chromium is present in an amount of about 0.125 mg, The therapeutic composition wherein orotic acid is present in an amount of about 325.0 mg and desferin is present in an amount of about 200.0 mg. The method of claim 1, wherein the allocriptopin is present in an amount of about 1.0 mg, nimodipine is present in an amount of about 20.0 mg, potassium iodide is present in an amount of about 120.0 mg, and potassium iodide is about 30.0 in an amount of mg, inulin is present in an amount of about 125.0 mg, silver is present in an amount of about 0.10 mg, zinc is present in an amount of about 10.0 mg, chromium is present in an amount of about 0.05 mg, The therapeutic composition wherein orotic acid is present in an amount of about 250.0 mg and desferin is present in an amount of about 100.0 mg. The method of claim 1, wherein the pharmaceutically effective amount is about 1: 20: 120: 30 of allocryptopin vs. nimodipine vs potassium iodide vs potassium iodide vs inulin vs silver vs zinc vs chromium vs orotic acid vs desperin: A therapeutic composition comprising a weight ratio of 125: 0.1: 10: 0.05: 250: 100. The therapeutic composition of claim 1, wherein the composition is in a form suitable for administration to a patient, wherein the form is selected from the group consisting of tablets, coated tablets, wafers, suppositories, effervescent powders, gels and colloidal suspensions. In the therapeutic composition for the treatment of HIV, the therapeutic composition is a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin, A composition consisting of taraxasterol and B-sitosterol. The method of claim 8, wherein the allocliptopin is present in an amount of about 1.0 mg to about 10.0 mg, nimodipine is present in an amount of about 20.0 mg to about 100.0 mg, and potassium iodide is about 120.0 mg to about 560.0 mg Potassium iodide in an amount of about 30.0 mg to about 140.0 mg, inulin is present in an amount of about 125.0 mg to about 375.0 mg, and silver is present in an amount of about 0.10 mg to about 0.50 mg Zinc is present in an amount of about 10.0 mg to about 20.0 mg, chromium is present in an amount of about 0.05 mg to about 0.20 mg, orotic acid is present in an amount of about 150.0 mg to about 500.0 mg, desferin The therapeutic composition is present in an amount of about 100.0 mg to about 300.0 mg, taraxasterol is present in an amount of about 250 mg to about 400 mg and B-sitosterol is present in an amount of about 300 mg to about 500 mg. 9. The method of claim 8, wherein the allocliptopin is present in an amount of about 10.0 mg, nimodipine is present in an amount of about 100.0 mg, potassium iodide is present in an amount of about 560.0 mg, and potassium iodide is about 140.0. in an amount of mg, inulin is present in an amount of about 375.0 mg, silver is present in an amount of about 0.50 mg, zinc is present in an amount of about 20.0 mg, chromium is present in an amount of about 0.20 mg, Theotropic acid is present in an amount of about 500.0 mg, desferin is present in an amount of about 300.0 mg, tarasosterol is present in an amount of about 400 mg, and B-sitosterol is present in an amount of about 500 mg. . 9. The method of claim 8, wherein the allocliptopin is present in an amount of about 4.5 mg, nimodipine is present in an amount of about 60.0 mg, potassium iodide is present in an amount of about 340.0 mg, and potassium iodide is about 85.0 in an amount of mg, inulin is present in an amount of about 250.0 mg, silver is present in an amount of about 0.30 mg, zinc is present in an amount of about 15.0 mg, chromium is present in an amount of about 0.125 mg, Theotropic acid is present in an amount of about 325.0 mg, desferin is present in an amount of about 200.0 mg, tarasosterol is present in an amount of about 350 mg, and B-sitosterol is present in an amount of about 400 mg. . 9. The method of claim 8, wherein the allocliptopin is present in an amount of about 1.0 mg, nimodipine is present in an amount of about 20.0 mg, potassium iodide is present in an amount of about 120.0 mg, and potassium iodide is about 30.0. in an amount of mg, inulin is present in an amount of about 125.0 mg, silver is present in an amount of about 0.10 mg, zinc is present in an amount of about 10.0 mg, chromium is present in an amount of about 0.05 mg, Theotropic acid is present in an amount of about 250.0 mg, desferin is present in an amount of about 100.0 mg, tarasosterol is present in an amount of about 250 mg, and B-sitosterol is present in an amount of about 300 mg. . Pharmaceutically effective amounts of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid, and so on to provide a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus infection A method for preparing a pharmaceutical mixture for preventing HIV virus replication comprising mixing desferin together. The method of claim 13, wherein said mixing step is carried out at room temperature. The method of claim 13, wherein the allocliptopin is present in an amount of about 1.0 mg to about 10.0 mg, nimodipine is present in an amount of about 20.0 mg to about 100.0 mg, and potassium iodide is about 120.0 mg to about 560.0 mg Potassium iodide in an amount of about 30.0 mg to about 140.0 mg, inulin is present in an amount of about 125.0 mg to about 375.0 mg, and silver is present in an amount of about 0.10 mg to about 0.50 mg Zinc is present in an amount of about 10.0 mg to about 20.0 mg, chromium is present in an amount of about 0.05 mg to about 0.20 mg, orotic acid is present in an amount of about 150.0 mg to about 500.0 mg and desferin It is present in an amount from about 100.0 mg to about 300.0 mg. The method of claim 13, wherein the allocliptopin is present in an amount of about 10.0 mg, nimodipine is present in an amount of about 100.0 mg, potassium iodide is present in an amount of about 560.0 mg, and potassium iodide is about 140.0 in an amount of mg, inulin is present in an amount of about 375.0 mg, silver is present in an amount of about 0.50 mg, zinc is present in an amount of about 20.0 mg, chromium is present in an amount of about 0.20 mg, Orotic acid is present in an amount of about 500.0 mg and desferin is present in an amount of about 300.0 mg. The method according to claim 13, wherein the allocliptopin is present in an amount of about 4.5 mg, nimodipine is present in an amount of about 60.0 mg, potassium iodide is present in an amount of about 340.0 mg, and potassium iodide is about 85.0 in an amount of mg, inulin is present in an amount of about 250.0 mg, silver is present in an amount of about 0.30 mg, zinc is present in an amount of about 15.0 mg, chromium is present in an amount of about 0.125 mg, Orotic acid is present in an amount of about 325.0 mg and desferin is present in an amount of about 200.0 mg. The method according to claim 13, wherein the allocliptopin is present in an amount of about 1.0 mg, nimodipine is present in an amount of about 20.0 mg, potassium iodide is present in an amount of about 120.0 mg, and potassium iodide is about 30.0 in an amount of mg, inulin is present in an amount of about 125.0 mg, silver is present in an amount of about 0.10 mg, zinc is present in an amount of about 10.0 mg, chromium is present in an amount of about 0.05 mg, Orotic acid is present in an amount of about 250.0 mg and desferin is present in an amount of about 100.0 mg. 14. The pharmaceutical mixture of claim 13, wherein the pharmaceutical mixture comprises about 1: 20: 120: 30: 125 of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin versus silver to zinc to chromium to orotic acid to desferin. And a weight ratio of: 0.1: 10: 0.05: 250: 100. The method of claim 13, further comprising converting the pharmaceutical mixture into a form suitable for administration to a patient, wherein the form is from a group consisting of tablets, coated tablets, wafers, suppositories, effervescent powders, gels and colloids. The method chosen. In a method for the treatment of HIV infection, the method comprises a pharmaceutical mixture comprising a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin. Administering to the patient in need of such treatment. The method of claim 21, wherein the pharmaceutical mixture is administered intramuscularly. The method of claim 21, wherein the pharmaceutical mixture is administered by intravenous injection. Pharmaceutically effective amounts of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid, to provide a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus infection A method for preparing a pharmaceutical mixture for preventing HIV virus replication comprising mixing together desferin, tarasosterol and B-sitosterol. The method of claim 24, wherein said mixing step is carried out at room temperature. 25. The method of claim 24, wherein the allocliptopine is present in an amount from about 1.0 mg to about 10.0 mg, nimodipine is present in an amount from about 20.0 mg to about 100.0 mg, and potassium iodide is from about 120.0 mg to about 560.0 mg Potassium iodide in an amount of about 30.0 mg to about 140.0 mg, inulin is present in an amount of about 125.0 mg to about 375.0 mg, and silver is present in an amount of about 0.10 mg to about 0.50 mg Zinc is present in an amount of about 10.0 mg to about 20.0 mg, chromium is present in an amount of about 0.05 mg to about 0.20 mg, orotic acid is present in an amount of about 150.0 mg to about 500.0 mg, desferin Which is present in an amount of about 100.0 mg to about 300.0 mg, taraxasterol is present in an amount of about 250 mg to about 400 mg and B-sitosterol is present in an amount of about 300 mg to about 500 mg. 25. The pharmaceutical mixture of claim 24, wherein the pharmaceutical mixture comprises about 1 of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin to silver to zinc to chromium to orotic acid to desferin to tarasasterol to B-sitosterol. And a weight ratio of: 20: 120: 30: 125: 0.1: 10: 0.05: 250: 100: 250: 300. The method of claim 24, further comprising converting the pharmaceutical mixture into a form suitable for administration to a patient, wherein the form is from a group consisting of tablets, coated tablets, wafers, suppositories, effervescent powders, gels and colloids. The method chosen. In a method for the treatment of HIV infection, the method comprises a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid, desferrin, tarasasterol and B -Administering a pharmaceutical mixture comprising cytosterol to a patient in need of such treatment. The method of claim 29, wherein the pharmaceutical mixture is administered intramuscularly. The method of claim 29, wherein the pharmaceutical mixture is administered by intravenous injection.